Reimbursement drug list total drugs vs Alzheimer's disease drug trial starts in China
Reimbursement drug list total drugs (point-in-time) and Alzheimer's disease drug trial starts (annual) in China. They are published at different intervals, so each is drawn on its own rather than matched period by period.
Change the pair
Compare different indicators
The series
Over time
China. Reimbursement drug list total drugs is published as point-in-time figures and alzheimer's disease drug trial starts as annual ones, so they are drawn on separate charts, clipped to 2024–2025, and no period is matched between them. Read each on its own.
Reimbursement drug list total drugs
Unit: count · 3 observations
No figure published for these periods
View the underlying data
| Period | Type | Value |
|---|---|---|
| as of 28 Nov 2024 | Actual | 3,159 |
| as of 1 Jan 2025 | Actual | 3,159 |
| as of 7 Dec 2025 | Actual | 3,253 |
Alzheimer's disease drug trial starts
Unit: count · 2 observations
Shared periods
Side by side
No period lines up: reimbursement drug list total drugs is point-in-time and alzheimer's disease drug trial starts is annual. A month and a year are not the same measurement window, so no row pairs them.
Provenance
Where these numbers come from
Reimbursement drug list total drugs
Total number of pharmaceutical products covered by a national or public reimbursement drug formulary.
3 observations charted in China · source organisations: NHSA, State Council
Alzheimer's disease drug trial starts
Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
2 observations charted in China (of 6 annual records) · source organisations: ClinicalTrials.gov
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring